vs

Side-by-side financial comparison of BATTALION OIL CORP (BATL) and Ginkgo Bioworks Holdings, Inc. (DNA). Click either name above to swap in a different company.

Ginkgo Bioworks Holdings, Inc. is the larger business by last-quarter revenue ($33.4M vs $31.6M, roughly 1.1× BATTALION OIL CORP). On growth, Ginkgo Bioworks Holdings, Inc. posted the faster year-over-year revenue change (-23.8% vs -36.1%). Over the past eight quarters, Ginkgo Bioworks Holdings, Inc.'s revenue compounded faster (-6.2% CAGR vs -20.1%).

Battalion Oil Corp is an independent energy company engaged in the exploration, development, and production of crude oil, natural gas, and natural gas liquids. It primarily operates assets in the Eagle Ford Shale region of South Texas, serving commercial and industrial clients across North American energy markets.

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

BATL vs DNA — Head-to-Head

Bigger by revenue
DNA
DNA
1.1× larger
DNA
$33.4M
$31.6M
BATL
Growing faster (revenue YoY)
DNA
DNA
+12.3% gap
DNA
-23.8%
-36.1%
BATL
Faster 2-yr revenue CAGR
DNA
DNA
Annualised
DNA
-6.2%
-20.1%
BATL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BATL
BATL
DNA
DNA
Revenue
$31.6M
$33.4M
Net Profit
$1.8M
Gross Margin
Operating Margin
-33.8%
-211.9%
Net Margin
5.7%
Revenue YoY
-36.1%
-23.8%
Net Profit YoY
108.1%
EPS (diluted)
$-0.77
$-1.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BATL
BATL
DNA
DNA
Q4 25
$31.6M
$33.4M
Q3 25
$43.4M
$38.8M
Q2 25
$42.6M
$49.6M
Q1 25
$47.4M
$48.3M
Q4 24
$49.5M
$43.8M
Q3 24
$45.1M
$89.0M
Q2 24
$49.1M
$56.2M
Q1 24
$49.5M
$37.9M
Net Profit
BATL
BATL
DNA
DNA
Q4 25
$1.8M
Q3 25
$-735.0K
$-80.8M
Q2 25
$4.8M
$-60.3M
Q1 25
$6.0M
$-91.0M
Q4 24
$-22.2M
Q3 24
$21.6M
$-56.4M
Q2 24
$-105.0K
$-217.2M
Q1 24
$-31.2M
$-165.9M
Operating Margin
BATL
BATL
DNA
DNA
Q4 25
-33.8%
-211.9%
Q3 25
1.9%
-231.8%
Q2 25
-0.4%
-132.1%
Q1 25
7.2%
-184.1%
Q4 24
-36.2%
-236.3%
Q3 24
2.3%
-62.0%
Q2 24
10.4%
-396.7%
Q1 24
0.0%
-469.1%
Net Margin
BATL
BATL
DNA
DNA
Q4 25
5.7%
Q3 25
-1.7%
-207.9%
Q2 25
11.3%
-121.6%
Q1 25
12.7%
-188.2%
Q4 24
-44.9%
Q3 24
48.0%
-63.3%
Q2 24
-0.2%
-386.4%
Q1 24
-63.0%
-437.3%
EPS (diluted)
BATL
BATL
DNA
DNA
Q4 25
$-0.77
$-1.41
Q3 25
$-0.91
$-1.45
Q2 25
$-0.21
$-1.10
Q1 25
$-0.35
$-1.68
Q4 24
$-1.47
$-1.91
Q3 24
$0.34
$-1.08
Q2 24
$-0.53
$-4.23
Q1 24
$-2.24
$-3.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BATL
BATL
DNA
DNA
Cash + ST InvestmentsLiquidity on hand
$28.0M
$422.6M
Total DebtLower is stronger
$208.1M
Stockholders' EquityBook value
$-32.8M
$508.6M
Total Assets
$460.7M
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BATL
BATL
DNA
DNA
Q4 25
$28.0M
$422.6M
Q3 25
$50.5M
$495.5M
Q2 25
$44.6M
$559.4M
Q1 25
$73.6M
$325.3M
Q4 24
$19.7M
$561.6M
Q3 24
$29.8M
$616.2M
Q2 24
$54.4M
$730.4M
Q1 24
$48.9M
$840.4M
Total Debt
BATL
BATL
DNA
DNA
Q4 25
$208.1M
Q3 25
$213.8M
Q2 25
$219.4M
Q1 25
$225.1M
Q4 24
$162.1M
Q3 24
$147.8M
Q2 24
$160.4M
Q1 24
$190.2M
Stockholders' Equity
BATL
BATL
DNA
DNA
Q4 25
$-32.8M
$508.6M
Q3 25
$-20.3M
$559.8M
Q2 25
$-5.2M
$613.0M
Q1 25
$-1.8M
$647.4M
Q4 24
$4.1M
$716.1M
Q3 24
$35.0M
$797.9M
Q2 24
$22.7M
$833.1M
Q1 24
$31.3M
$987.3M
Total Assets
BATL
BATL
DNA
DNA
Q4 25
$460.7M
$1.1B
Q3 25
$491.7M
$1.2B
Q2 25
$498.8M
$1.2B
Q1 25
$506.2M
$1.3B
Q4 24
$431.0M
$1.4B
Q3 24
$458.0M
$1.5B
Q2 24
$487.3M
$1.6B
Q1 24
$488.6M
$1.6B
Debt / Equity
BATL
BATL
DNA
DNA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
39.35×
Q3 24
4.23×
Q2 24
7.07×
Q1 24
6.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BATL
BATL
DNA
DNA
Operating Cash FlowLast quarter
$-11.8M
$-47.7M
Free Cash FlowOCF − Capex
$-47.7M
FCF MarginFCF / Revenue
-142.8%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
-6.58×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BATL
BATL
DNA
DNA
Q4 25
$-11.8M
$-47.7M
Q3 25
$28.0M
$-31.6M
Q2 25
$10.2M
$-40.3M
Q1 25
$12.7M
$-51.5M
Q4 24
$6.7M
$-42.4M
Q3 24
$-5.1M
$-103.5M
Q2 24
$29.8M
$-84.4M
Q1 24
$3.9M
$-89.3M
Free Cash Flow
BATL
BATL
DNA
DNA
Q4 25
$-47.7M
Q3 25
Q2 25
$-40.3M
Q1 25
$-59.1M
Q4 24
$-56.1M
Q3 24
$-118.6M
Q2 24
$-111.4M
Q1 24
$-96.0M
FCF Margin
BATL
BATL
DNA
DNA
Q4 25
-142.8%
Q3 25
Q2 25
-81.2%
Q1 25
-122.4%
Q4 24
-128.0%
Q3 24
-133.2%
Q2 24
-198.2%
Q1 24
-252.9%
Capex Intensity
BATL
BATL
DNA
DNA
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.1%
Q1 25
15.8%
Q4 24
31.3%
Q3 24
16.9%
Q2 24
48.1%
Q1 24
17.7%
Cash Conversion
BATL
BATL
DNA
DNA
Q4 25
-6.58×
Q3 25
Q2 25
2.13×
Q1 25
2.11×
Q4 24
Q3 24
-0.23×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BATL
BATL

Oil$28.6M91%
Natural Gas Liquids Reserves$3.9M12%

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

Related Comparisons